Stocksigma LogoStocksigma Logo

Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up

Morepen Laboratories reported record Q2 FY27 revenue of Rs. 755 Cr, up 81% YoY, with EBITDA surging 273% YoY to Rs

Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up

Morepen Laboratories Ltd 路 Press Release 路 27 Oct 2026, 7:09 pm

Morepen Laboratories Reports Record Q2 FY27 Driven by Robust CDMO Scale-Up Morepen Laboratories reported record Q2 FY27 revenue of Rs. 755 Cr, up 81% YoY, with EBITDA surging 273% YoY to Rs. 132 Cr as margins expanded 897 bps to 17.45%. PAT rose 117% YoY to Rs. 89 Cr. Growth was propelled by commercial CDMO scale-up, generating Rs. 253 Cr in Q2 (52% of API+CDMO revenue). Exports jumped 131% to Rs. 397 Cr, and Medical Devices grew 65% to Rs. 208 Cr. API+CDMO capacity reached 614 KL, targeting 800 KL by Q2 FY28.

Original exchange filing (PDF)

More announcements from Morepen Laboratories Ltd

All Morepen Laboratories Ltd announcements